More tools:
Markets
·
Screener
·
Research
·
Chat
Atrium Therapeutics, Inc. Common Stock (RNA) Financial Statements
Atrium Therapeutics, Inc. Common Stock
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG01Z0T3B63
XNAS · usd
11.35
▼ 2.84 (-20.01%)
As of 2026-09-08
1M
6M
1Y
Valuation
Market Cap
$194.1M
Enterprise Value
—
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
—
Net Income (TTM)
—
EBITDA
—
Diluted EPS (TTM)
—
EBITDA Margin
—
Net Debt
—
Trading Information
Previous Close
14.19
Day's Range
10.75 – 14.19
52-Week Range
10.75 – 73.06
Volume
1.7M
Avg Volume
195.8K
Share Statistics
Shares Outstanding
17.1M
Employees
391
Exchange
XNAS
Listed
2026-02-27
Share count as of August 3, 2026
View
Income Statement
Balance Sheet
Cash Flow
Key Metrics
Valuation
Comparable Companies
Notes & Facts
DCF Model
Earnings Calls
Guidance
Presentations
Detail
Standard
Detailed
Period
Annual
Quarterly
TTM
Loading Income Statement…
Key questions about Atrium Therapeutics, Inc. Common Stock (RNA)
What is Atrium Therapeutics, Inc. Common Stock's Market Cap?
Atrium Therapeutics, Inc. Common Stock's Market Cap is $194.1M, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Subscribe
Income Statement
(in thousands of USD, except per-share data)
Source: Akyla.ai
Line Item
Jun 30, 2026
Mar 31, 2026
Jun 30, 2025
Mar 31, 2025
Collaboration revenue
3,004.0
19,635.0
Operating expenses:
Research and development
15,343.0
16,657.0
General and administrative
10,279.0
20,258.0
Total operating expenses
25,622.0
36,915.0
% of revenue
852.9%
188.0%
Loss from operations
(22,618.0)
(17,280.0)
% of revenue
-752.9%
-88.0%
Other income (expense)
Interest income
2,104.0
—
Other income (expense), net
328.0
—
Total other income (expense)
2,432.0
647.0
Net loss
(20,186.0)
(16,633.0)
% of revenue
-672.0%
-84.7%
Basic net loss per common share
(1.18)
(0.97)
Diluted net loss per common share
(1.18)
(0.97)